Allergy Diagnosis; Immunotherapy; Primary Prevention; Secondary Prevention; Sublingual Immunotherapy
- Pediatric Allergology and Pulmonology
Research Area: Pediatric Allergology: Primary food allergies (IgE- and non-IgE-mediated),new markers of diagnosis (BAT), food challenges; allergen-specific preventive immuntherapy trial in 4 year old children Pediatric Pulmonology: cystic fibrosis treatment trials
Zsolt Szépfalusi is M.D. and trained pediatrician with specialty in pediatric allergology and pulmonology. Early scientific activities focused on IgE-mediated allergies and in particular on the mode of materno-fetal interaction with allergic sensitization (1993-1996). On an ex-vivo placenta model experimental data support the idea of an early materno-fetal allergen-cross talk (1998-2005), that seems to be a Th1-driven response. (2006-2012). Clinical studies have been started to elucidate the early and preventive effect of allergen-specific immunotherapy in young children (2005-ongoing). The first placebo-controlled, sensitization-preventive sublingual immunotherapy trial (2008-2012) showed immuno-modulatory effects in actively treated (2014). A confirmatory placebo-controlled trial is under investigation (2018-2022). In cross-sectional, prospective and immunological studies the particular Th2-driving capacity of tacrolimus in organ transplantation could be shown (2006-2014). New biomarkers are needed for food allergy diagnosis. The role of the high-affinity FcERI is studied in vitro and in various types of IgE- and non-IgE-mediated allergies (2007-2021) in order to delineate possible biomarkers. Covid-19 infection also affects children. In a recent large cross-sectional study on 2069 schoolchildren in Vienna a PCR-prevalence of 0.1% (n=2) and a seroprevalence of 1.3% (n=26) was observed.
Techniques, methods & infrastructure
- food challenges (clinical)
- other provocation tests (unspecific, specific)
- flow cytometry
- cell culture (proliferation, cytokine detection, inhibition assays)
- IgE immunoblotting
- basophil activation test (BAT)
- Early allergen-specific immunotherapy to prevent the development of allergy (2020)
Source of Funding: Medical University of Vienna, Danube Allergy Research Cluster
- Hydroxychloroquine in pediatric ILD (2017)
Source of Funding: FWF (Austrian Science Fund), E-Rare Joint Transnational Call
- Román‐Carrasco, P. et al., 2019. Only α‐Gal bound to lipids, but not to proteins, is transported across enterocytes as an IgE‐reactive molecule that can induce effector cell activation. Allergy, 74(10), pp.1956–1968. Available at: http://dx.doi.org/10.1111/all.13873.
- Ponce, M. et al., 2019. Preventive sublingual immunotherapy with House Dust Mite extract modulates epitope diversity in pre‐school children. Allergy, 74(4), pp.780–787. Available at: http://dx.doi.org/10.1111/all.13658.
- Moñino‐Romero, S. et al., 2019. Soluble Fcɛ RI : A biomarker for IgE‐mediated diseases. Allergy, 74(7), pp.1381–1384. Available at: http://dx.doi.org/10.1111/all.13734.
- Moñino-Romero, S. et al., 2018. The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses. Allergy, 74(2), pp.236–245. Available at: http://dx.doi.org/10.1111/all.13567.
- Szépfalusi, Z. et al., 2021. Lessons from low seroprevalence of SARS‐CoV‐2 antibodies in schoolchildren: A cross‐sectional study C. Riggioni, ed. Pediatric Allergy and Immunology. Available at: http://dx.doi.org/10.1111/pai.13459.